It's Time For Novartis To Put Its Leqvio Launch Strategy To The Test
Executive Summary
Novartis Pharmaceuticals US head Victor Bulto talks to Scrip about the launch of Leqvio; the cholesterol-lowering medicine now approved by the US FDA.
You may also be interested in...
Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.
First-In-Class Drugs Made Up More Than Half Of US FDA’s Novel Approvals Last Year
CDER hit a high mark with 27 first-in-class approvals in the 50 novel agents cleared in 2021.
Novartis Opts For Alliance Rather Than Acquisition With Alnylam
The announcement that the Swiss giant is collaborating again with Alnylam could spark fresh speculation that the firms are moving closer to a merger – or not.